Abstract:Li Yuan Wei, 1, * Xiao Jun Zhang, 1, * Li Wang, 2 Li Na Hu, 3 Xu Dong Zhang, 4, 5 Li Li, 3 Jin Nan Gao 1 1 Department of Breast Surgery, Shanxi Bethune Hospital, Taiyuan, People's Republic of China; 2 School of Basic Medicine Sciences, Academy of Medical Science, Zhengzhou University, Henan 450053, People's Republic of China; 3 Department of Pathology, Shanxi Bethune Hospital, Taiyuan, People's Republic of China; 4 Translational Research Institute, Henan Provincial People's Hospital, Academy of Medical Science, Zhengzhou University, Henan 450053, People's Republic of China; 5 School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia *These authors contributed equally to this work Correspondence: Jin Nan Gao Department of Breast Surgery, Shanxi Bethune Hospital, Taiyuan 030000, People's Republic of China Tel +86 0351- 8379761 Email sxjinnan@aliyun.com Li Li Department of Pathology, Shanxi Bethune Hospital, Taiyuan 030000, People's Republic of China Tel +86-13453163501 Email limuzi73@163.com Purpose: Pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) is associated with favourable outcomes of patients with triple-negative breast cancer (TNBC). However, a proportion of TNBC patients with the residual disease do not relapse and achieve long-term survival. The aim of this study was to identify biomarkers that predict clinical outcomes in these patients. Patients and Methods: A retrospective series of 10 TNBC patients who displayed non-pCR to NACT were included in the discovery cohort. Total RNA from pre-NACT core biopsies and paired surgical specimens were subjected to the Affymetrix Human Transcriptome Array. Gene set enrichment analysis (GSEA) was used to identify signal pathways and gene signatures associated with metastasis. The Cox proportional hazard model and Kaplan–Meier survival curves were employed to assess the prognostic value of the identified signature in two independent TNBC datasets included in Gene Expression Omnibus (GEO). Results: The epithelial–mesenchymal transition (EMT) pathway was markedly more enriched in pre- (NES = 1.92; p.adjust = 0.019) and post-NACT samples (NES = 2.02; p.adjust = 0.010) from patients who developed metastasis after NACT. A subset of 6 EMT genes including LUM, SFRP4, COL6A3, MMP2, CXCL12 , and HTRA1 were expressed constantly at higher levels in samples from patients who progressed to metastatic disease. The potential of the 6-EMT gene signature to predict TNBC metastasis after NACT was validated with a GEO dataset (HR=0.36, p=0.0008, 95% CI: 0.200– 0.658). Moreover, the signature appeared of predictive value in another GEO dataset of TNBC patients who received surgery followed by adjuvant chemotherapy (HR = 0.46, 95% CI: 0.225– 0.937). Conclusion: Expression analysis of the 6-EMT gene signature at diagnosis may be of predictive value for metastasis in TNCB patients who did not achieve pCR to NACT and for patients treated with surgery in combination with adjuvant therapy. Keywords: triple-negative breast cancer, neoadjuvant chemotherapy, epithelial–mesenchymal transition, distant metastasis

Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior

Abstract P5-04-03: Epithelial-mesenchymal Transition is Associated with in Situ to Invasive Transition of Basal-Like Breast Cancer

Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer

Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis

Association of Epithelial to Mesenchymal Transition with Efficacy of Egfr-Tkis in Non-Small Cell Lung Cancer Patients with Egfr Wild Type

Epithelial-Mesenchymal Transition Indexes in Triple-Negative Breast Cancer Progression and Metastases

Epithelial-mesenchymal transition status of circulating tumor cells in breast cancer and its clinical relevance

Epithelial-type Systemic Breast Carcinoma Cells with a Restricted Mesenchymal Transition Are a Major Source of Metastasis

A Six-Epithelial–Mesenchymal Transition Gene Signature May Predict Metastasis of Triple-Negative Breast Cancer

Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients

Single-cell analysis of breast cancer metastasis reveals epithelial-mesenchymal plasticity signatures associated with poor outcomes

P3-015: Clinicopathologic Features and Epidermal Growth Factor Receptor Mutations Associated with Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer

Clinical significance of epithelial–mesenchymal transition-related markers expression in the micrometastatic sentinel lymph node of NSCLC

Epithelial-To-Mesenchymal Transition In Human Esophageal Cancer Associates With Tumor Progression And Patient'S Survival

Immunohistochemical Analysis of Transcription Factors and Markers of Epithelial–Mesenchymal Transition (EMT) in Human Tumors

The Epithelial-Mesenchymal Transition Phenotype of Metastatic Lymph Nodes Impacts the Prognosis of Esophageal Squamous Cell Carcinoma Patients.

Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin

Clinical Significance of Epithelial-Mesenchymal Transition-Related Molecules in Lung Adenocarcinoma.

Differential expression and clinical significance of epithelial-mesenchymal transition markers among different histological types of triple-negative breast cancer

Prognostic Value of Epithelial-Mesenchymal Transition Markers in Clear Cell Renal Cell Carcinoma.

EMT Dynamics in Lymph Node Metastasis of Oral Squamous Cell Carcinoma